Skip to content
The Nexus
DossierENTITY

vemurafenib

Coverage of vemurafenib in the Nexus archive.

Earliest in view: Apr 15 · 00:00 UTCMost recent: Apr 15 · 00:00 UTC
Co-mentioned in this coverage
PerturbFatetopic1Natureorganization1melanomatopic1CRISPR interferencetopic1
Recent coverage
  • SCIENCEApr 15 · 00:00 UTCNATURE NEWS
    Mapping convergent regulators of melanoma drug resistance by PerturbFate

    PerturbFate, a high-throughput single-cell platform, identifies common regulatory nodes and phenotypic states linked to vemurafenib resistance in melanoma cells. The study, published in Nature, uses CRISPR interference to map convergent regulators of drug resistance in melanoma.

vemurafenib · Dossier · The Nexus